P-350 An improved personalized medicine network: The PLATON from GI and beyond

Personalized medicine aims to treat patients individually according their biological and molecular features by directly targeting tumor-specific markers. Gastrointestinal cancers (GIC), despite different treatment strategies, still have a high recurrence mortality rate. Like in all other cancers, targeted therapies are also clinical trials for GICs, but the monitorization of therapy success needs improvement. The PLATON Network (PLATON, NCT05489250) is an interactive precision oncology network that improve personalized interlinking scientists, allowing them view/follow patients’ profiles recruit new ongoing implement substudies or benefit from BioDataBank within Network. mostly covers GIC together with various tumor entities. can be considered as umbrella structure subprojects, screening tool molecular-driven trials. enrolls during prior first-line collects information on routine data (baseline data, histopathology reports, decisions, etc.). During follow-up, anti-tumor lines, response, survival quality life recorded. Importantly, able offer testing e.g. Foundation CDx Liquid provide reports pathology case discussions its own board experts. cases compatible external NGS through evaluation central review medical advisors. conducted Institute Clinical Cancer Research (IKF) Frankfurt. In so far, total 217 (138 male (m) 79 female (f)) complete standardized capture report results enrolled 34 sites. mean age 64(m)/67(f) (min: 21(m)/24(f) max: 88(m)/87(f)). Within diagnostic cohorts, GICs consist 48 esophagogastric cancer, 59 intra-/extrahepatic cholangiocellular carcinoma additionally 17 gallbladder carcinoma, 35 hepatocellular cancer 58 pancreatic cancer. individual observational status 112 out patients, while 92 died 10 715 days after enrollment. Out cases, 143 were discussed detail educational series project ”Molecular Pathology Case Discussion”. total, 3070 genetic alterations detected 1817 variants unknown significance (VUS). A mutational burden (TMB) over up 67 mutations/mb could 30 cases. This study shows feasibility PLATON, especially GIC. obtained not only patient-specific follow-up baseline further projects substudies. PLATON’s interactive, multicenter, prospective cohort provides well-annotated managed translational research GIs. grow studies open participation.